Internationally Renowned Medical Oncologist Robert L. Capizzi, MD, to
Head Department of Medicine
Robert L. Capizzi, MD, has been named Magee Professor of Medicine
and department chairman, effective April 1, 1996, according to the announcement
made by Joseph S. Gonnella, MD, senior vice president for academic affairs
and dean, Jefferson Medical College.
"Dr. Capizzi's past experience as a division head at an academic medical
center, director of one of the nation's 26 NCI-designated comprehensive
cancer centers and as a executive in a private-sector bioscience company
involved in drug development, will enhance Jefferson's ability to support
our mission of patient care, education and research. And there is no question
that he will be a vital player as we expand our clinical trials activity,"
Dr. Gonnella said. Dr. Capizzi, who will assume his new position on July
1, succeeds José F. Caro as chairman of the department.
Dr. Capizzi, who comes to Jefferson after serving as executive vice president,
Worldwide Research & Development for U.S. Bioscience, Inc. in West Conshohocken,
has been an adjunct professor of pharmacology at Jefferson Medical College
since 1992. While at U.S. Bioscience, Inc., for the past four and one-half
years, Dr. Capizzi functioned as the chief scientific officer with leadership
of the staff conducting laboratory and clinical research in the United States,
Europe and Canada. These efforts culminated in regulatory approvals in international
markets for Neutrexin for the treatment of pneumocystis carinii pneumonia
and Ethyol, the first broad spectrum cytoprotective agent in oncology. Dr.
Capizzi was also involved in the scientific aspects of corporate alliances
with other major pharmaceutical firms that are responsible for marketing
and sales of U.S. Bioscience drugs in various countries.
Before joining U.S. Bioscience, Dr. Capizzi had been the Charles L. Spurr
Professor of Medicine, head of the section of hematology/oncology and director
of the cancer center at the Bowman Gray School of Medicine of Wake Forest
University, in Winston-Salem, North Carolina. During Dr. Capizzi's leadership,
the cancer center received NCI peer review and award as one of the nation's
26 comprehensive cancer centers. He also served as the chairman of the Piedmont
Oncology Association, an NIH-supported oncology clinical trials network
throughout five states of the southeastern United States.
Before that time, Dr. Capizzi was co-director of the division of hematology/oncology
at the University of North Carolina School of Medicine in Chapel Hill after
having served there as professor of medicine and pharmacology and chief
of the division of medical oncology. Dr. Capizzi also served in the section
of medical oncology at the Yale University School of Medicine, where he
had been associate professor of medicine and pharmacology, and scholar of
the Howard Hughes Medical Institute at Yale. Dr. Capizzi is board-certified
in internal medicine and medical oncology.
Dr. Capizzi's many professional activities include executive positions in
many professional societies and service on the Council for Research and
Clinical Investigations Awards for the American Cancer Society (National
Office), many NIH panels and study sections and the oncology drug advisory
panel of the FDA. He is associate editor for Cancer Research, and
he also serves on the editorial boards of Cancer Drug Delivery, Hematologic
Pathology, Current Opinion in Oncology, Cancer Biotherapy and the Journal
Dr. Capizzi is a fellow in the American College of Physicians, and his other
professional memberships include Alpha Omega Alpha National Medical Honor
Society, American Association for Cancer Research, American Society of Clinical
Oncology, American College of Physicians, American Medical Association,
and the Pennsylvania Oncologic Society. He is the recipient of the U.S.
Army Meritorious Service Medal and the FDA Commissioner's Citation of Merit
for service to the FDA.
Dr. Capizzi is author or co-author of chapters for 26 books, 128 journal
articles and approximately 200 abstracts on drug development and chemotherapy
for leukemia, lung, colorectal, ovarian and breast cancer.